Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.51 |
| ▸ | NFE2 | Q16621 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185484 | 0.86 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL1012411 | 0.85 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL15008960 | 0.85 | JAK2 (0.48) | MAPK14MAPK13MAPK12MAPK11HPGD | |
| SCHEMBL1012616 | 0.85 | MAPK13 (0.66) | MAPK14MAPK13MAPK12MAPK11HPGD | |
| SCHEMBL4510854 | 0.84 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1015668 | 0.83 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL15026596 | 0.83 | JAK2 (0.46) | MAPK14MAPK13MAPK12MAPK11HPGD | |
| SCHEMBL1012863 | 0.82 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1011007 | 0.82 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| Carbamic Acid SCHEMBL1780358 | 0.82 | MAPK13 (0.62) | MAPK14MAPK13MAPK12MAPK11JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101773-B2 | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101773-B2 | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101773-B2 | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2134677-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL)PHENYL]-1H-PYRAZOL-5-YL}CARBAMOYL)-AMINO]-3-CHLOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2134677-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL)PHENYL]-1H-PYRAZOL-5-YL}CARBAMOYL)-AMINO]-3-CHLOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2111401-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2111401-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2134677-A2 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL)PHENYL]-1H-PYRAZOL-5-YL}CARBAMOYL)-AMINO]-3-CHLOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2111401-A1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008079968-A1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO] -3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079968-A1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO] -3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079972-A2 | 4-{4- [ ({3-TERT-BUTYL-1- [3- (HYDROXYMETHYL) PHENYL] - 1H- PYRAZOL- 5 -YL } CARBAMOYL) -AMIN O] -3-CHLOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079972-A2 | 4-{4- [ ({3-TERT-BUTYL-1- [3- (HYDROXYMETHYL) PHENYL] - 1H- PYRAZOL- 5 -YL } CARBAMOYL) -AMIN O] -3-CHLOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | TP53, DOT1L, VHL | MAPK14 2665/4885MAPK13 3282/4885MAPK12 3489/4885 |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | TP53, MGMT, VHL | MAPK14 2068/4885MAPK13 2367/4885MAPK12 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.